PROTHENA CORP PLC (PRTA)

IE00B91XRN20 - Common Stock

17.22  +0.44 (+2.62%)

After market: 16.36 -0.86 (-4.99%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

PROTHENA CORP PLC

NASDAQ:PRTA (10/11/2024, 8:21:20 PM)

After market: 16.36 -0.86 (-4.99%)

17.22

+0.44 (+2.62%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-22.57%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap926.09M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PRTA Daily chart

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Company Info

PROTHENA CORP PLC

77 Sir John Rogersons Quay, Block C, Grand Canal Docklands

DUBLIN D02 VK60

P: 35312362500

CEO: Gene G. Kinney

Employees: 173

Website: https://www.prothena.com/

PRTA News

ChartMill News Image13 days ago - ChartmillWhat's going on in today's session

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

News Image13 days ago - Market News VideoProthena Enters Oversold Territory (PRTA)
ChartMill News Image13 days ago - ChartmillTraders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

News Image15 days ago - Prothena Corporation plcProthena Announces Leadership Team Updates
News Imagea month ago - Prothena Corporation plcProthena to Participate in Upcoming Healthcare Conferences
News Image2 months ago - InvestorPlacePRTA Stock Earnings: Prothena Corp Beats EPS, Beats Revenue for Q2 2024

PRTA stock results show that Prothena Corp beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

PRTA Twits

Here you can normally see the latest stock twits on PRTA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example